Inlay

ProfilePosts

📰Disease-modifying effect of efruxifermin in compensated cirrhosis due to MASH: To miss the forest for the tree(s) 👉Cirrhosis regression only partially captures the potential therapeutic benefit of disease-modifying drugs in phase 3 🖇️ for explanation: authors.elsevier.com/sd/article/S...

😀🇦🇹 multisociety (gastroenterology & hepatology, diabetology & obesity) consensus on MASLD (& MetALD!) 🤝Well-aligned with @easlnews.bsky.social CPGs 😟Reimbursement currently restricted to semaglutide for T2DM 🤔Reimbursement in your country? 🖇️: rdcu.be/eLAde #LiverSky @georg-semmler.bsky.social

Overview on published/presented data on MASH cirrhosis #LiverSky @bavenocoop.bsky.social 🖇️: authors.elsevier.com/sd/article/S...

I am very sad. My mentor and friend, Jaume Bosch, just has passed away. Thanks for everything, I will miss you. I would always remember our last day together celebrating a journey we begin together @hospitalclinic.bsky.social @idibaps.bsky.social

🖤 With deep sorrow, we announce the passing of Prof. Dr. Jaime Bosch, President of the Baveno Cooperation. A brilliant scientist, inspiring leader, and dear friend. His immense legacy in hepatology will endure. Rest in peace, Jaime

@bavenocoop.bsky.social visiting the Japanese Society of Portal Hypertension 👀 at our auditorium 🙏 incredible hospitality 👉 See our 🇯🇵 friends at Baveno VIII

How often do u get asked to “clear” patients w/cirrhosis for surgery? How about “just” being on board? #liversky Well, if u want to get on board, here is your next read 👇🏼 Guidelines on abdominal surgery in patients w/cirrhosis @jhepatology.bsky.social www.journal-of-hepatology.eu/article/S016...

8mo

7mo

8mo

Monitoring resmetirom by LSM - asking for the moon? Oftentimes mentioned but even more often forgotten: ❗️Random variation of LSM by VCTE exceeds 25% 👉🔽 LSM >25% often by chance, same for 'unchanged' or increases 👉No substitute for clinical judgement #LiverSky @georg-semmler.bsky.social 🔗👇